GFAP and Alzheimer disease: The analysis of serum GFAP in our AD cohort revealed a significant increase compared to the non-neurodegenerative and non-inflammatory controls, which is in agreement with earlier studies (Oeckl et al., 2019; Oeckl et al., 2022; Benedet et al., 2021).